Aerie Pharmaceuticals Inc (OQ:AERI)

Business Focus: Bio Therapeutic Drugs

Jul 09, 2019 02:30 am ET
Aerie Pharmaceuticals Completes Enrollment of the Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Months Ahead of Schedule
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that enrollment for its Phase 2 clinical trial of netarsudil ophthalmic solution in Japan is complete, a milestone reached several months earlier than previously anticipated.
Jun 17, 2019 02:30 am ET
Aerie Pharmaceuticals Announces Appointment of Jeffrey Calabrese, CPA, as Director of Accounting
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of Jeffrey Calabrese, CPA, as Director of Accounting, reporting to Christopher Staten, Aerie’s Vice President of Finance. Mr. Calabrese will lead external financial reporting, technical accounting and equity accounting. He most recently held relate
Jun 11, 2019 03:30 am ET
Aerie Pharmaceuticals to Present at Two Upcoming Investor Conferences
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Richard Rubino, Chief Financial Officer, will present an Aerie overview and provide a business update at two upcoming investor conferences:
May 28, 2019 03:30 am ET
Aerie Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference on Tuesday, June 4, 2019 at 2:30 p.m. Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and provide a business updat
May 07, 2019 12:01 pm ET
Aerie Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today reported financial results for the first quarter ended March 31, 2019, along with a general business update.
May 02, 2019 02:33 pm ET
Aerie Pharmaceuticals Announces Additional Undrawn $100M Credit Facility with Deerfield Management, Increasing Availability to $200M
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that it has entered into an amendment of its existing credit agreement with certain affiliates of Deerfield Management Company L.P. (Deerfield).
May 01, 2019 02:30 am ET
Aerie Pharmaceuticals Announces U.S. Launch of Rocklatan® and Increase in Rhopressa® Medicare Part D Coverage to Approximately 75% of Lives
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that it has launched Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% into the United States glaucoma market. Rocklatan® is now with national and regional U.S. pharmaceutical wholesalers, and patients can fill prescri
Apr 30, 2019 03:30 am ET
Aerie Pharmaceuticals to Announce First Quarter 2019 Financial Results and Host Conference Call on Tuesday, May 7, 2019
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye announced today that its first quarter 2019 financial results will be released after the market closes on Tuesday, May 7, 2019. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and
Apr 25, 2019 02:30 am ET
Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-13503 Sustained Release Implant
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that the U.S. Food and Drug Administration (FDA) has reviewed the Investigational New Drug Application (IND) for AR-13503, a novel multi-kinase (Rho kinase/Protein kinase C (ROCK/PKC)) inhibitor sustained-release implant (the AR-13503 implant) and it is now in
Apr 02, 2019 03:30 am ET
Aerie Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019 at 1:30 p.m. Eastern Time in New York, NY. Dr. Anido will provide an A
Apr 01, 2019 02:30 am ET
Aerie Pharmaceuticals Announces Appointment of Gianluca Corbinelli as Chief Commercial Officer - Europe
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of Gianluca Corbinelli as Chief Commercial Officer - Europe, reporting to Thomas Mitro, Aerie’s President and Chief Operating Officer. Mr. Corbinelli will be responsible for overseeing the execution of all aspects of Aerie’s commercialization activ
Mar 25, 2019 02:30 am ET
Aerie Pharmaceuticals Announces Four Appointments
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of David Ellis, Ph.D., as Director, Chemistry, reporting to Mitchell deLong, Ph.D., Aerie’s Vice President of Chemistry. Dr. Ellis will be responsible for advancing the Company’s creation and optimization of new chemical entities to support the gro
Mar 21, 2019 02:30 am ET
Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Designed to Support Requirements for Future Regulatory Filing
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced the commencement of patient dosing in its Phase 2 clinical trial designed in accordance with the requirements of Japan’s PMDA (Pharmaceuticals and Medical Devices Agency) to support potential regulatory submission of netarsudil ophthalmic solution
Mar 18, 2019 02:30 am ET
Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced the commencement of patient dosing in a Phase 2 clinical trial of AR-1105, its investigational dexamethasone intravitreal implant, in patients with macular edema due to retinal vein occlusion (RVO).
Mar 12, 2019 02:30 pm ET
Aerie Pharmaceuticals Announces Full-Year 2019 Net Revenue and Net Cash Burn Guidance
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced full-year 2019 net revenue and net cash burn guidance.
Mar 12, 2019 02:20 pm ET
Aerie Pharmaceuticals Announces U.S. FDA Approval of Rocklatan™ (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the Reduction of Intraocular Pressure in Patients with Open-Angle Glau
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that the U.S. Food and Drug Administration (FDA) has approved Rocklatan™ (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular
Mar 05, 2019 02:30 am ET
Aerie Pharmaceuticals to Present at Two Investor Conferences in March
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present an Aerie overview and provide a business update in a fireside discussion at the following conferences in March.
Mar 01, 2019 03:25 am ET
New Research Coverage Highlights Micron Technology, Varian Medical, St. Joe, Himax Technologies, Aerie Pharmaceuticals, and Hexcel — Consolidated Revenues, Company Growth, and Expectations for 2019
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Micron Technology, Inc. (NASDAQ:MU), Varian Medical Systems, Inc. (NYSE:VAR),...
Feb 25, 2019 11:01 am ET
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results, Provides 2019 Cash Burn Guidance and Business Update
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2018, along with 2019 cash burn guidance and a general business update.
Feb 19, 2019 02:30 am ET
Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Monday, February 25, 2019
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye announced today that its fourth quarter and full year 2018 financial results will be released after the market closes on Monday, February 25, 2019. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s f
Jan 17, 2019 01:30 am ET
Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-1105 (Dexamethasone Intravitreal Implant)
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye today announced that the U.S. Food and Drug Administration (FDA) has reviewed the Investigational New Drug Application (IND) for AR-1105 (dexamethasone intravitreal implant) and it is now in effect, allowing Aerie to initiate human studies in the treatment of macular edema due to
Jan 04, 2019 01:30 am ET
Aerie Pharmaceuticals Announces Positive Topline Results of Netarsudil Ophthalmic Solution in Pilot Phase 2 Study Supporting Clinical Development in Japan
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye today announced the topline results of its pilot Phase 2 study of netarsudil ophthalmic solution in a Japanese-American population. The study was designed in accordance with the requirements of Japan’s PMDA (Pharmaceuticals and Medical Devices Agency) to support the potential regu
Jan 02, 2019 01:30 am ET
Aerie Pharmaceuticals Announces Appointment of Ami Bavishi as Director, Investor Relations and Vincent Santucci, Pharm.D., as Director, Scientific Market Access
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced the appointment of Ami Bavishi as Director, Investor Relations, reporting to Richard Rubino, Aerie’s Chief Financial Officer. Ms. Bavishi will drive all of Aerie’s investor relations activities, and joins Aerie from Burns McClellan, a public relations and investor
Dec 04, 2018 02:20 am ET
Investor Expectations to Drive Momentum within Mirati Therapeutics, comScore, Nuance Communications, Carnival, Aerie Pharmaceuticals, and TrueCar — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mirati Therapeutics, Inc. (NASDAQ:MRTX), comScore, Inc. (NASDAQ:SCOR),...
Nov 07, 2018 02:30 am ET
Aerie Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Stifel 2018 Healthcare Conference on Tuesday, November 13, 2018 at 10:15 a.m. Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview
Nov 06, 2018 11:01 am ET
Aerie Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today reported financial results for the third quarter ended September 30, 2018, along with a general business update.
Oct 30, 2018 03:30 am ET
Aerie Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 6, 2018
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its third quarter 2018 financial results will be released after the market closes on Tuesday, November 6, 2018. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update.
Oct 25, 2018 04:30 am ET
Report: Exploring Fundamental Drivers Behind Invitae, Aerie Pharmaceuticals, Gevo, Global Medical REIT, Cyclacel Pharmaceuticals, and Toll Brothers — New Horizons, Emerging Trends, and Upcoming Develo
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Invitae Corporation (NYSE:NVTA), Aerie Pharmaceuticals, Inc....
Oct 23, 2018 02:30 am ET
Aerie Pharmaceuticals Establishes GMP PRINT® Production Facility in an Expanded Global Headquarters
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that it has built and commenced operation of its GMP (Good Manufacturing Practices)-validated manufacturing facility for production of ophthalmic implants using the proprietary PRINT® (Particle Replication in Non-wetting Templates) Technology platform
Oct 09, 2018 02:30 am ET
Aerie Pharmaceuticals, Inc. Announces Drug Application for Regulatory Approval Accepted for Review in Europe
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today reported that the EMA has accepted for review the MAA for Rhokiinsa® (netarsudil ophthalmic solution) 0.02%. Rhokiinsa® is currently marketed as Rhopressa® in the United States and is indicated for the reduction of elevated intraocular press
Sep 25, 2018 03:30 am ET
Aerie Pharmaceuticals to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that Richard Rubino, Chief Financial Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference on Tuesday, October 2, 2018 at 2:15 p.m. Eastern Time in New York, NY. Mr. Rubino will provide an Aerie overview and business update.
Sep 24, 2018 02:30 am ET
Aerie Pharmaceuticals Announces Appointment of Damien Monaghan, Quality Director
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced the appointment of Damien Monaghan, Quality Director, reporting to Finbar O’Neill, EU Director, Quality & Regulatory Compliance. Mr. Monaghan will lead quality assurance and quality control operations for Aerie’s manufacturing plant in Athlone, Ireland. Mr. Monagh
Sep 13, 2018 02:30 am ET
Aerie Pharmaceuticals to Present at Ophthalmology Futures Forums in Vienna, Austria
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that Richard Rubino, Chief Financial Officer, will present at the Ophthalmology Futures European Forum held prior to the 36th Congress of the European Society of Cataract and Refractive Surgeons on Thursday, September 20, 2018 at 9:57 a.m. Central European Time i
Sep 12, 2018 12:01 pm ET
Aerie Pharmaceuticals Appoints David W. Gryska to the Company’s Board of Directors
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that David W. Gryska has been appointed to the Company’s Board of Directors and will also be a member of the Audit Committee of the Board. David brings extensive executive level healthcare-focused and financial leadership experience from large global biopharmaceut
Sep 11, 2018 12:01 pm ET
Aerie Pharmaceuticals Announces Appointment of Robert Finan as Director of Finance
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced the appointment of Robert Finan, Director of Finance, reporting to Christopher Staten, Vice President of Finance. Mr. Finan will lead Aerie’s finance, operations and strategy activities for Aerie’s manufacturing plant in Athlone, Ireland. Mr. Finan most recently h
Sep 10, 2018 02:30 am ET
Aerie Pharmaceuticals Announces Appointment of Thomas A. Shepard as Vice President, Implant Manufacturing
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced the appointment of Thomas A. Shepard as Vice President, Implant Manufacturing, reporting to Casey Kopczynski, Ph.D., Aerie’s Chief Scientific Officer. Mr. Shepard will lead Aerie’s implant manufacturing facility in Durham, North Carolina, including responsibility
Sep 05, 2018 03:30 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Aerie Pharmaceuticals, BioScrip, Celsion, Primoris Services, Cyclacel Pharmaceuticals, and Barnes Group — New Research Emphasizes Ec
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), BioScrip, Inc. (NASDAQ:BIOS),...
Aug 20, 2018 02:30 am ET
Aerie Pharmaceuticals Announces Appointment of Jeffrey White, Ph.D. as Director, Toxicology and Pharmacokinetics
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced the appointment of Jeffrey White, Ph.D. as Director, Toxicology and Pharmacokinetics, reporting to Eric Carlson, Ph.D., Aerie’s Vice President of Research and Development. Dr. White will have operational and scientific responsibility for Aerie’s nonclinical develo
Aug 16, 2018 04:20 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within inTest, Hooker Furniture, American Public Education, Gevo, Envestnet, and Aerie Pharmaceuticals — New Research Emphasizes Economic G
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of inTest Corporation (NYSE:INTT), Hooker Furniture Corporation...
Aug 15, 2018 02:30 am ET
Aerie Pharmaceuticals Reports Topline Result from Rhopressa® Mechanism of Action Study
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced topline efficacy results from a double-masked, randomized, placebo-controlled study (AR-13324-CS206; NCT03233308) designed to evaluate the effect of Rhopressa® (netarsudil ophthalmic solution) 0.02% on aqueous humor dynamics in patients with open-angle
Aug 08, 2018 12:01 pm ET
Aerie Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today reported financial results for the second quarter ended June 30, 2018, along with a general business update.
Aug 02, 2018 03:30 am ET
Aerie Pharmaceuticals to Present at the Canaccord Genuity Growth Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that Richard Rubino, Chief Financial Officer, will present in a fireside chat discussion at the Canaccord Genuity Growth Conference on Thursday, August 9, 2018 at 1:30 p.m. Eastern Time in Boston, MA. Mr. Rubino will provide an Aerie overview and business update.
Aug 01, 2018 03:30 am ET
Aerie Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Wednesday, August 8, 2018
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its second quarter 2018 financial results will be released after the market closes on Wednesday, August 8, 2018. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update.
Aug 01, 2018 02:30 am ET
Aerie Pharmaceuticals, Inc. and DSM Biomedical, Inc. Expand Collaboration Agreement Focused on Novel Drug Delivery Technology in Ophthalmology
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, and DSM Biomedical, Inc., a global solutions provider in biomedical science and regenerative medicine, today reported that they have expanded their collaborative research, development, and license agreement.
Jul 23, 2018 03:30 am ET
Aerie Pharmaceuticals Announces Deerfield’s Conversion of Convertible Notes into Aerie Common Stock and Establishment of an Undrawn $100M Credit Facility with Deerfield
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that the $125 million of senior secured convertible notes held by affiliates (the “holders”) of Deerfield Management Company L.P. (“Deerfield”) since September 2014 have been fully converted into 5,040,323 shares of Aerie common stock in accordance with their term
Jul 23, 2018 02:30 am ET
Aerie Pharmaceuticals Announces Early Notification of FDA Acceptance of NDA Submission for Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% with PDUFA Date Set for March 14, 2019
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today reported that it has received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) earlier than scheduled, the FDA has completed its initial 60-day review of the NDA (new drug application) for Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02
Jul 16, 2018 02:30 am ET
Aerie Pharmaceuticals Announces Appointment of Randall Brown as Director, Payer Marketing
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Randall Brown as Director, Payer Marketing, reporting to Deanne Melloy, Aerie’s Vice President of Marketing. Mr. Brown will support the ongoing development and execution of strategies, programs and communication activities for the payer markets. Mr. Brown previo
Jun 18, 2018 02:30 am ET
Aerie Pharmaceuticals Announces Appointment of William Coppola as Intellectual Property Counsel
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of William Coppola as Intellectual Property Counsel, reporting to John LaRocca, Aerie’s General Counsel. Mr. Coppola will oversee intellectual property matters both domestically and internationally on behalf of the Company. Mr. Coppola previously held related posit
Jun 14, 2018 03:30 am ET
Aerie Pharmaceuticals to Present at the JMP Securities 2018 Life Science Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that Richard Rubino, Chief Financial Officer, will present in a fireside chat discussion at the JMP Securities 2018 Life Science Conference on Thursday, June 21, 2018 at 2:00pm Eastern Time in New York, NY. Mr. Rubino will provide an Aerie overview and business update.
Jun 06, 2018 03:30 am ET
Aerie Pharmaceuticals to Present at the NASDAQ 38th Investor Conference
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that Richard Rubino, Chief Financial Officer, will present at the NASDAQ 38th Investor Conference on Tuesday, June 12, 2018 at 9:00am British Summer Time in London, UK. Mr. Rubino will provide an Aerie overview and business update.
May 31, 2018 03:30 am ET
Aerie Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present at the Jefferies 2018 Global Healthcare Conference on Tuesday, June 5, 2018 at 4:30pm Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and business update.
May 30, 2018 02:30 am ET
Aerie Pharmaceuticals Announces Appointment of Lily Nguyen as Director, Project Management
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Lily Nguyen as Director, Project Management, reporting to Kenneth Ruettimann, Ph.D., Aerie’s Vice President of Manufacturing. Ms. Nguyen will direct strategic plan development and oversee ongoing project progress in the manufacturing department. Ms. Nguyen previ
May 15, 2018 02:30 am ET
Aerie Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%. RoclatanTM is a once-daily eye drop designed to reduce intraocular pressure (IOP) in pati
May 08, 2018 12:01 pm ET
Aerie Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today reported financial results for the first quarter ended March 31, 2018, along with a general business update.
May 03, 2018 04:10 am ET
Investor Expectations to Drive Momentum within Roper Technologies, Inter Parfums, SunCoke Energy Partners, Aerie Pharmaceuticals, Forrester Research, and Diamond Hill Investment Group — Discovering Un
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Roper Technologies, Inc. (NYSE:ROP), Inter Parfums, Inc. (NASDAQ:IPAR),...
May 01, 2018 02:30 am ET
Aerie Pharmaceuticals Announces Appointment of Concetta Perro as Commercial Counsel
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Concetta Perro as Commercial Counsel, reporting to John LaRocca, Aerie’s General Counsel. Ms. Perro will direct a broad spectrum of commercial contracting activities. Ms. Perro previously held a related position at GE Healthcare Life Sciences, a division of GE H
Apr 30, 2018 02:30 am ET
Aerie Pharmaceuticals Announces U.S. Launch of Rhopressa® (netarsudil ophthalmic solution) 0.02%
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that it has launched Rhopressa® in the United States. Rhopressa® is now in national and regional U.S. pharmaceutical distributors, and patients have access to Rhopressa® through their local pharmacies across the nation.
Apr 26, 2018 03:30 am ET
Aerie Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Tuesday, May 8, 2018
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its first quarter 2018 financial results will be released after the market closes on Tuesday, May 8, 2018. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update.
Apr 12, 2018 02:30 am ET
Aerie Pharmaceuticals Announces Appointment of Scott Laranjo as Director, Marketing, Roclatan™
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Scott Laranjo as Director, Marketing, RoclatanTM, reporting to Deanne Melloy, Aerie’s Vice President of Marketing. Mr. Laranjo will direct future marketing activities associated with RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0
Mar 21, 2018 03:55 am ET
Investor Expectations to Drive Momentum within JELD-WEN Holding, Nathan's Famous, Aerie Pharmaceuticals, RBC Bearings, Malibu Boats, and United Therapeutics — Discovering Underlying Factors of Influen
NEW YORK, March 21, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of JELD-WEN Holding, Inc. (NYSE:JELD), Nathan's Famous,...
Mar 21, 2018 03:30 am ET
Aerie Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside chat discussion at the 17th Annual Needham Healthcare Conference on Tuesday, March 27, 2018 at 4:00pm Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview
Mar 14, 2018 03:30 am ET
Aerie Pharmaceuticals to Present at the Oppenheimer & Co. 28th Annual Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that Richard Rubino, Chief Financial Officer, will present in a fireside chat discussion at the Oppenheimer & Co. 28th Annual Healthcare Conference on Tuesday, March 20, 2018 at 8:00am Eastern Time in New York, NY. Mr. Rubino will provide an Aerie overview and business
Mar 07, 2018 02:30 am ET
Aerie Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside chat discussion at the Cowen and Company 38th Annual Health Care Conference on Tuesday, March 13, 2018 at 10:40am Eastern Time in Boston, MA. Dr. Anido will provide an Aerie
Feb 28, 2018 11:01 am ET
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update and 2018 Guidance
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2017, along with a general business update and 2018 guidance.
Feb 21, 2018 02:30 am ET
Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Wednesday, February 28, 2018
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its fourth quarter and full year 2017 financial results will be released after the market closes on Wednesday, February 28, 2018. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update and 2018 guidance.
Feb 20, 2018 01:30 am ET
Aerie Pharmaceuticals Announces Appointment of John LaRocca as General Counsel
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of John LaRocca as General Counsel, reporting to Vicente Anido, Jr., Ph.D., Aerie’s Chairman and Chief Executive Officer. Mr. LaRocca will oversee all legal matters for the Company. He was previously Executive Vice President and General Counsel at Eagle Pharmaceuti
Feb 12, 2018 01:30 am ET
Aerie Pharmaceuticals Announces Appointment of Scott Cassady as Regional Sales Director for the Central Region
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Scott Cassady as Regional Sales Director for the Central Region, reporting to Gary Menichini, Aerie’s Vice President of Sales. Mr. Cassady will direct the activities of the Company’s district sales managers and territory managers in the Central region of the Uni
Feb 08, 2018 01:30 am ET
Aerie Pharmaceuticals Announces Appointment of Brad Fuller as Director of National Accounts in its Market Access Department
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Brad Fuller as Director of National Accounts, reporting to Dale Seibt, Aerie’s Vice President of Market Access. As a member of the Market Access Department, Mr. Fuller will focus on gaining formulary access for Aerie’s approved products in his territory. He pre
Feb 01, 2018 01:30 am ET
Aerie Pharmaceuticals Announces Appointment of Tad Heitmann as Head of Communications
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Tad Heitmann as Head of Communications, reporting to Judith Robertson, Aerie’s Chief Commercial Officer. Mr. Heitmann will head Aerie’s corporate, commercial and internal communications activities. He previously held leadership positions at BioComm Network, Inc
Jan 23, 2018 11:03 am ET
Aerie Pharmaceuticals Announces Public Offering of Common Stock
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma or ocular hypertension and other diseases of the eye, today announced that it has commenced a registered underwritten public offering of $75 million of shares of its common stock. The underwriter will have a 30-day option from the date of the offering to purchase up to an additional $11.25 million of shares of common stock.
Jan 19, 2018 02:45 am ET
Market Trends Toward New Normal in Aerie Pharmaceuticals, Martin Midstream Partners, PTC, Powell Industries, BancFirst, and Saul Centers — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Jan. 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), Martin Midstream...
Jan 16, 2018 01:30 am ET
Aerie Pharmaceuticals Announces Appointments of Nils Hauptmann as Director of Regulatory Affairs and Pharmacovigilance and Tim Swan as Director of Sales and Transparency Operations
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointments of Nils Hauptmann as Director of Regulatory Affairs and Pharmacovigilance, reporting to Cindy Martin, Aerie’s Vice President of Regulatory, and Tim Swan as Director of Sales and Transparency Operations, reporting to Gerry McKenzie, Aerie’s Vice President of
Jan 02, 2018 01:30 am ET
Aerie Pharmaceuticals Announces Appointment of Julia Williams as Director of Medical Affairs
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Julia Williams as Director of Medical Affairs, reporting to John Maltman, Ph.D., Aerie’s Vice President of Medical Affairs. Ms. Williams will participate in directing the strategic and operational activities of the Company’s Medical Affairs organization, initia
Dec 18, 2017 10:52 am ET
Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa® (netarsudil ophthalmic solution) 0.02% for the Lowering of Elevated Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that the U.S. Food and Drug Administration (FDA) has approved Rhopressa® (netarsudil ophthalmic solution) 0.02% for the lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. A link to the ful
Dec 04, 2017 01:30 am ET
Aerie Pharmaceuticals Announces Appointment of Heather Johnson as Regional Sales Director for the Northeast Region
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Heather Johnson as Regional Sales Director for the Northeast Region, reporting to Gary Menichini, Aerie’s Vice President of Sales. Ms. Johnson will direct the activities of the Company’s district sales managers and territory managers in the Northeastern region of the United St
Dec 01, 2017 01:30 am ET
Aerie Pharmaceuticals Announces Appointment of Paul Bae as Vice President of Human Resources
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Paul Bae as Vice President of Human Resources, reporting to Kathy McGinley, Aerie’s Vice President of Human Resources and Corporate Services. Mr. Bae will be responsible for leading the strategic human resources effort to recruit, develop and retain employees in the U.S., with
Nov 27, 2017 01:30 am ET
Aerie Pharmaceuticals Announces Appointment of Nhi Ong as Director of Analytics
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Nhi Ong as Director of Analytics, reporting to Gerry McKenzie, Aerie’s Vice President of Commercial Operations. Mr. Ong will be responsible for directing the information and analytics functions in support of Aerie’s commercial organization. He previously held related positions
Nov 16, 2017 11:01 am ET
Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements of Regulatory Filing in Japan
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced the commencement of patient dosing in its Phase 2 clinical trial designed in accordance with the requirements of Japan’s PMDA (Pharmaceuticals and Medical Devices Agency) for potential regulatory submission of netarsudil ophthalmic solution in Japan. Netarsudil
Nov 08, 2017 11:01 am ET
Aerie Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the third quarter ended September 30, 2017, along with a general business update.
Nov 07, 2017 02:30 am ET
Aerie Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside chat discussion at the Stifel 2017 Healthcare Conference on Tuesday, November 14, 2017 at 2:00 p.m. Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and business
Nov 01, 2017 03:30 am ET
Aerie Pharmaceuticals to Announce Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its third quarter 2017 financial results will be released after the market closes on Wednesday, November 8, 2017. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update.
Oct 30, 2017 02:30 am ET
Aerie Pharmaceuticals Announces Appointment of John Maltman, Ph.D., as Vice President of Medical Affairs
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of John Maltman, Ph.D., as Vice President of Medical Affairs, reporting to Theresa Heah, M.D., M.B.A., Aerie’s Vice President of Clinical Research and Medical Affairs. Dr. Maltman will be responsible for leading the strategic efforts of Aerie’s Medical Affairs Department across a
Oct 20, 2017 04:10 am ET
Oct 13, 2017 09:55 am ET
Aerie Pharmaceuticals Announces FDA Advisory Committee Vote in Favor of Rhopressa™ (netarsudil ophthalmic solution) 0.02%
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that, in their review of Aerie product candidate RhopressaTM (netarsudil ophthalmic solution) 0.02%, the members of Dermatologic and Ophthalmic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted as follows on the two points for
Oct 13, 2017 03:05 am ET
Aerie Pharmaceuticals Stock Trading Halted Today
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that NASDAQ has halted trading of the Company’s common stock. A meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has been scheduled for today to review the Company’s New Drug Application (NDA) for Rh
Oct 09, 2017 02:30 am ET
Aerie Pharmaceuticals Announces Appointment of New Members of its Research and Development Team
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of 11 employees to its Research and Development team located in Durham, NC. The new employees will initially focus on preclinical activities associated with the drug delivery asset acquisition from Envisia Therapeutics announced on October 5, 2017.
Oct 05, 2017 02:00 am ET
Aerie Pharmaceuticals Announces Drug Delivery Asset Acquisition to Further Advance Its Retinal Disease Program
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that it has acquired from Envisia Therapeutics Inc. (Envisia) the rights to use PRINT® technology in ophthalmology and certain other assets. The PRINT® technology is a proprietary system capable of creating precisely engineered sustained release products utilizing
May 26, 2017 06:31 am ET
InvestorsObserver releases covered-call reports for ACADIA Pharmaceuticals, Aerie Pharmaceuticals, Best Buy Inc., Marathon Oil Corporation and Walgreens Boots Alliance
CHICAGO, May 26, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACAD, AERI, BBY, MRO, and WBA....